Aevi Genomic Medicine, Inc.

▎药明康德内容团队编辑日前，Avalo Therapeutics宣布收购AlmataBio公司并获得已进入临床2期阶段的白介素-1β（IL-1β）靶向单克隆抗体AVTX-009。同时，Avalo完成1.85亿美元的私募融资，其中包含初始前期投资1.156亿美元。该融资由Commodore Capital和TCGX领投，BVF Partners、Deep Track Capital、OrbiMed、Petrichor和RA Capital Management参与。AVTX-009是一款人源化单克隆抗体（IgG4），能够与IL-1β高度亲和地结合并抑制其活性。IL-1β是炎症反应的关键因素，其过量产生或调控失衡与多种自身免疫和炎症性疾病密切相关，是这些疾病治疗的重要、经过验证的靶点。先前的研究表明，通过抑制IL-1β，可以有效治疗化脓性汗腺炎（HS）和其他皮肤科、胃肠科、风湿科的炎症性疾病。Avalo计划持续推进AVTX-009作为治疗化脓性汗腺炎的药物开发。预计该药物针对HS的临床2期试验的主要结果将在2026年发布。除HS外，Avalo还打算将AVTX-009用于至少一种其他类型的慢性炎症性疾病的治疗。▲Avalo Therapeutics管线图（图片来源：Avalo Therapeutics公司官网）Garry A. Neil博士现任Avalo Therapeutics的首席执行官。在此之前，自2020年2月Avalo与生物技术公司Aevi Genomic Medicine完成合并以来，Neil博士一直在Avalo担任高级科学顾问及首席科学官职务。他曾在2013年9月至2020年2月期间，担任Aevi Genomic Medicine公司的首席科学官。在加入Aevi之前，Neil博士是生命科学风险投资公司Apple Tree Partners的合伙人，并曾在包括强生在内的多家著名药企中担任过重要职务。大家都在看药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million. Retrieved March 29, 2024 from https://ir.avalotx.com/press-releases/detail/183/avalo-acquires-anti-il-1-mab-and-announces-private免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

DUBLIN, June 22, 2023 /PRNewswire/ -- The "Global Genomics Partnering Terms and Agreements 2016 to 2023" report has been added to ResearchAndMarkets.com's offering. The Global Genomics Partnering Terms and Agreements 2016 to 2023 report provides an understanding and access to the genomics partnering deals and agreements entered into by the world's leading healthcare companies. Trends in genomics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Genomics partnering contract documents Top genomics deals by value The Global Genomics Partnering Terms and Agreements report provides an understanding and access to the genomics partnering deals and agreements entered into by the world's leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter genomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors genomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains links to online copies of actual genomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an orientation of genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in genomics dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading genomics deals since 2016. Deals are listed by headline value, signed by big pharma, most active genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomics dealmaking with a brief summary followed by a comprehensive listing of genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2016. The chapter is organized by specific genomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by genomics partnering company A-Z, deal type definitions and genomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in genomics partnering and dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genomics technologies and products. Report scope Global Genomics Partnering Terms and Agreements 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to genomics trends and structure of deals entered into by leading companies worldwide. Global Genomics Partnering Terms and Agreements 2016 to 2023 includes: Trends in genomics dealmaking in the biopharma industry since 2016 Access to headline, upfront, milestone and royalty data Access to over 800 genomics deal records and contract documents where available The leading genomics deals by value since 2016 Most active genomics dealmakers since 2016 The leading genomics partnering resources In Global Genomics Partnering Terms and Agreements 2016 to 2023, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy and technology target Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in genomics dealmaking 2.1. Introduction 2.2. Genomics partnering over the years 2.3. Most active genomics dealmakers 2.4. Genomics partnering by deal type 2.5. Genomics partnering by therapy area 2.6. Deal terms for genomics partnering 2.6.1 Genomics partnering headline values 2.6.2 Genomics deal upfront payments 2.6.3 Genomics deal milestone payments 2.6.4 Genomics royalty rates Chapter 3 - Leading genomics deals 3.1. Introduction 3.2. Top genomics deals by value Chapter 4 - Most active genomics dealmakers 4.1. Introduction 4.2. Most active genomics dealmakers 4.3. Most active genomics partnering company profiles Chapter 5 - Genomics contracts dealmaking directory 5.1. Introduction 5.2. Genomics contracts dealmaking directory Chapter 6 - Genomics dealmaking by technology type Companies Mentioned 1CellBiO 2bPrecise 2seventy bio 3 Sisters Surrogacy 3D Signatures 4baseCare 10X Genomics 14M Genomics 22nd Century 23andMe A*STAR Agency for Science Technology and Research A*STAR Bioinformatics Institute A*STAR Genome Institute of Singapore Abbvie Abcam Abramson Cancer Center Absorption Systems Academia Sinica Accelerated Cure Project for MS Accelerate Technologies Access to Comprehensive Genomic Profiling Coalition Acerta Pharma ACMG Foundation for Genetic and Genomic Medicine ACT Genomics Active Motif ActX Adaptimmune Adaptive Biotechnologies ADInstruments Admera Health Adrestia Advaita ADx Healthcare Aelan Cell Technologies Aevi Genomic Medicine Affymetrix AgBiome Agendia Agilent Technologies Agribody Technologies Agriplex Genomics AiLife Diagnostics Aitbiotech Akadeum Life Sciences AKESOgen Alana Healthcare Albany Molecular Research Alexion Pharmaceuticals AllCells Allele Biotechnology and Pharmaceuticals Almac Diagnostics Alnylam Pharmaceuticals ALS Association ALS Automated Lab Solutions Altor BioScience Alzheimer's Drug Discovery Foundation Amazon Web Services Ambry Genetics America's Choice Provider Network American Physiological Society American Society of Clinical Oncology (ASCO) American Type Culture Collection (ATCC) Amgen Amplicon Express Analytical BioSciences Anam Hospital Angsana Molecular & Diagnostics AnimalBiome Annoroad APG Bio Applied Biosystems Aptorum Group Arbor Biotechnologies Arcadia Biosciences Arc Bio ArcherDX Arcturus Therapeutics Argonaut Arima Genomics Arzeda Aslan Pharma Astellas Pharma AstraZeneca Astrea Forensics Athletigen Atlas Genetics Atlas Genomics ATUM Auria Biobank Avance Biosciences Avera Health Avera Heart Hospital of South Dakota Avvinity Therapeutics Axil Scientific B-MoGen Biotechnologies Baheal Pharmaceutical Bank of America Banner Health BASF Battelle Bayer Bayer CropScience Bayer Healthcare Baylor College of Medicine Baylor Genetics Baylor Miraca Genetics Laboratories BC Platforms BD Biosciences Beckman Coulter Becton Dickinson Beijing Genomics Institute (BGI) Beijing InnoCare Pharma Belgian Society of Medical Oncology Benson Hill Biosystems Berkeley Lights Berry Genomics Beth Israel Deaconess Medical Center BGI BGI Americas Bill and Melinda Gates Foundation Bina Technologies Bio-Rad Laboratories Bio-Techne BioBright Biocartis Biocept Biodesix BioDiscovery BioFire Diagnostics Biogen BioIntelliSense BioIQ BioLegend BioMap BioMarin Pharmaceutical Biomecite Diagnostics Biomedical Advanced Research and Development Authority BioMed X Innovation Center Biomillenia BioNano Genomics BioNova Cientifica BioReference Laboratories BioSkryb Biosplice Biostar BioTheranostics Biotop Blackfynn Blockchain Global Bluebird Bio Blue Cross Blue Shield Association For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer – – Michael C. Diem, M.D., promoted to Chief Financial Officer – – Hy Levitsky, M.D., rejoins as President of Research and Development – PHILADELPHIA, April 12, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Greg Russotti, Ph.D., as ad-interim Chief Executive Officer, effective April 11, 2023. Dr. Russotti, who has served as the Company’s Chief Technology Officer since January 2020, is succeeding Lalo Flores, Ph.D., who has stepped down as Chief Executive Officer and as a member of the Company’s Board of Directors to pursue other opportunities. In addition, effective April 11, 2023, Michael C. Diem, M.D., was promoted to the role of Chief Financial Officer, and Hy Levitsky, M.D., assumed his prior role as President of Research and Development. The Board of Directors has commenced a search to identify a permanent Chief Executive Officer. “Lalo has played a key role in advancing Century, a premier cell therapy company, to where it is today. On behalf of the entire Board of Directors, we wish Lalo success and thank him for his service,” said Joe Jimenez, Chairman of the Board. “Greg is a true leader in the cell therapy space who we believe can build upon the Company’s strong foundation with his significant clinical and commercial expertise. As Century enters an exciting new stage of growth, we look forward to continuing to leverage his extensive experience.” Mr. Jimenez added, “Additionally, I would like to congratulate Mike Diem on his promotion to Chief Financial Officer, and I am pleased to welcome Hy Levitsky back to Century. Both Mike and Hy have been instrumental in Century’s success to date, and we look forward to their continued contributions as the Company advances its next generation platform and robust portfolio of cell therapy product candidates.” Greg Russotti, Ph.D., ad-interim Chief Executive Officer Prior to joining Century, Dr. Russotti served as Vice President of Cell Therapy Development and Operations at Celgene. While at Celgene, he guided chemistry, manufacturing and controls efforts for five different cell therapy products to clinical-stage development. Dr. Russotti was also a leader in establishing in-house clinical manufacturing at Celgene, and in building Celgene’s first commercial CAR T manufacturing facility. Prior to Celgene, he held various leadership roles at Merck Research Laboratories, developing vaccines and monoclonal antibodies for clinical and commercial manufacturing. He received his B.S. and M.S. degrees in Chemical Engineering from Rensselaer Polytechnic Institute, and his Ph.D. in Chemical and Biochemical Engineering from Rutgers University. Dr. Russotti has held a visiting professorship in Rutgers Biomedical Engineering department since 2008. He also serves as Industrial Executive Board Member of the Marcus Center for the Commercialization of Cell Therapies at Georgia Tech, and as an Executive Committee member of the National Science Foundation-funded Center for the Manufacturing of Advanced Therapeutics at Georgia Tech. “I am honored to assume this role, and I look forward to building upon our accomplishments to date to execute on our vision of delivering transformative allogeneic cell therapies to patients,” said Dr Russotti. “With a solid balance sheet, which we expect to fund operations into 2026, we believe we are well-positioned to continue to deliver on our key platform and program milestones.” Michael C. Diem, M.D., Chief Financial Officer Dr. Diem, who joined Century in 2020, most recently served as the Company’s Chief Business Officer. Prior to joining Century, he was Senior Vice President of Business and Corporate Development at Amicus Therapeutics, and prior to that, he held a similar role at Aevi Genomic Medicine. Earlier in his career, Dr. Diem was the Global Head of Corporate Strategy and Corporate Development at AstraZeneca, where he was responsible for mergers and acquisitions, divestitures, and managed the company’s strategic investment activities and MedImmune Ventures. At GlaxoSmithKline (GSK), he led business development for the Company’s rare disease business unit, and was also a partner in GSK’s corporate venture firm, SR One, Limited. Dr. Diem obtained his M.D. from the Rutgers-Robert Wood Johnson Medical School, and an M.B.A. from Case Western Reserve University. He completed his medical training at Duke University and is a Kauffman Fellow. Hy Levitsky, M.D., President of Research and Development Dr. Levitsky previously served as Century’s President, Research and Development from 2019 until early 2023. Prior to joining the Company, he served as Executive Vice President and Chief Scientific Officer at Juno Therapeutics, Inc., and was also Head of Cancer Immunotherapy Experimental Medicine at F. Hoffmann-La Roche & Co. Previously, Dr. Levitsky was Professor of Oncology, Medicine, and Urology at The Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, and the Scientific Director of the George Santos Bone Marrow Transplant Program at The Johns Hopkins University. He currently serves as a member of the Board of Directors of Replimune, Prokarium, and Carisma Therapeutics. Dr. Levitsky obtained his M.D. from The Johns Hopkins University School of Medicine. About Century Therapeutics Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit . Century Therapeutics Forward-Looking Statement This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to obtain FDA acceptance for our future IND submissions and commence clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic, geopolitical issues and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. For More Information: Company: Elizabeth Krutoholow – investor.relations@centurytx.com Investors and Media: Melissa Forst/Maghan Meyers – century@argotpartners.com